Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

      Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

      Drug pricing scrutiny, pricing and competitive pressure, and major pipeline setbacks can hurt the performance of the large-cap pharmaceuticals sector in the short term.

        Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

        Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

          Company News For Jun 15, 2018

          Companies In The News are: ETSY,RCL,MYL,GSK,TWTR

            Mylan (MYL) to Get CRL Again for Generic Advair from FDA

            Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

              Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication

              Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.

                The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

                The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

                  Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

                  Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

                    Mark Vickery headshot

                    Top Stock Reports for Chevron, Glaxo & T-Mobile

                    Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS).

                      Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

                      Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

                        Merck Presents Positive Melanoma Data on Keytruda at ASCO

                        Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.

                          LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics

                          LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.

                            Novartis Announces Positive Data on Kisqali and Tasigna

                            Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.

                              Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO

                              Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.

                                LabCorp Extends Aetna Agreement, Expands Diagnostics Business

                                The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.

                                  Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

                                  Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

                                    AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

                                    AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

                                      The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

                                      The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

                                        Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                                        Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                                          AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                                          AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                                            Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

                                            Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                                              Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                                              Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                                                HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                                                Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                                                  Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

                                                  Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.